Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc. is a biotechnology company dedicated to discovering, developing and providing novel, small molecule drugs that significantly improve the lives of patients with immune and hematological disorders, cancer and rare diseases. Rigel's pioneering research focuses on signaling pathways that are critical to disease mechanisms. Its clinical programs include clinical trials of fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, in a number of indications. The Company has submitted an NDA to the FDA for fostamatinib in patients with chronic or persistent ITP. The investigation of fostamatinib also includes Phase 2 clinical trials for autoimmune hemolytic anemia and IgA nephropathy.

Company Growth (employees)
Type
Public
HQ
South San Francisco, US
Founded
1996
Size (employees)
77 (est)-38%
Website
rigel.com
Rigel Pharmaceuticals was founded in 1996 and is headquartered in South San Francisco, US

Key People at Rigel Pharmaceuticals

Raul R. Rodriguez

Raul R. Rodriguez

President & CEO
Frank Torti

Frank Torti

Investor
Elliott B. Grossbard

Elliott B. Grossbard

Advisor

Rigel Pharmaceuticals Office Locations

Rigel Pharmaceuticals has an office in South San Francisco
South San Francisco, US (HQ)
1180 Veterans Boulevard

Rigel Pharmaceuticals Data and Metrics

Rigel Pharmaceuticals Financial Metrics

USD

Net income (FY, 2016)

(69.2 m)

EBIT (FY, 2016)

(69.7 m)

Market capitalization (10-Jul-2017)

304.9 m

Closing share price (10-Jul-2017)

2.7

Cash (31-Dec-2016)

17.6 m
Rigel Pharmaceuticals's current market capitalization is $304.9 m.
USDFY, 2016

R&D expense

63.4 m

General and administrative expense

20.9 m

Operating expense total

90.1 m

EBIT

(69.7 m)

Interest income

437 k

Net Income

(69.2 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

20.9 m15.2 m43.5 m17.6 m

Accounts Receivable

5.8 m5.8 m203 k

Current Assets

220.1 m150.5 m129 m76.2 m

PP&E

4.5 m2.5 m1.6 m1.2 m

Total Assets

226.1 m154.1 m131.7 m78.1 m

Accounts Payable

3.9 m1.6 m2.8 m5.6 m

Current Liabilities

10.3 m14 m33.8 m22.6 m

Additional Paid-in Capital

1.1 b1.1 b1.1 b1.1 b

Retained Earnings

(849.3 m)(940.2 m)(991.6 m)(1.1 b)

Total Equity

208.3 m128.2 m91.4 m55 m

Financial Leverage

1.1 x1.2 x1.4 x1.4 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(89 m)(90.9 m)(51.5 m)(69.2 m)

Depreciation and Amortization

2.6 m2.4 m1.4 m941 k

Accounts Receivable

(5.8 m)(5.8 m)5.5 m203 k

Inventories

1.9 m722 k

Accounts Payable

2.2 m(2.3 m)1.2 m2.8 m

Cash From Operating Activities

(86.1 m)(69.8 m)(23.4 m)(75.9 m)

Capital Expenditures

(1.2 m)(413 k)(546 k)(804 k)

Cash From Investing Activities

72.4 m62.9 m44.6 m24.9 m

Cash From Financing Activities

1.1 m1.2 m7.1 m25.2 m

Free Cash Flow

(84.8 m)(69.3 m)(22.9 m)(76.7 m)
Y, 2016

Financial Leverage

1.4 x

Rigel Pharmaceuticals Market Value History

Rigel Pharmaceuticals Online and Social Media Presence

Rigel Pharmaceuticals Company Life and Culture

You may also be interested in